PIPELINE
Sovargen will continue to expand competitive pipelines through our
proprietary science and technology.
- Sovargen R&D Pipeline
- Neurodevelopmental disorders Brain Tumor
Pipeline / Indication | Target identification |
Hit Screening |
Lead Optimization |
IND- Enabling |
Phase 1 | Phase 2 |
---|---|---|---|---|---|---|
SVG103 FCD II1),TSC2), PROS3) |
|
|||||
SVG105
Intractable focal epilepsy including FCD II, TSC |
|
|||||
SVG301 glioma |
|
|||||
SVG303 GBM |
|
|||||
SVG30X Brain Tumor |
|
SVG103 FCD II1),TSC2), PROS3)
SVG105
Intractable focal epilepsy
including FCD II, TSC
SVG301 glioma
SVG303 GBM
SVG30X Brain Tumor
- Focal Cortical Dysplasia
- Tuberous Sclerosis Complex
- PIK3CA-related overgrowth spectrum
Partnership
Sovargen will expedite and strengthen drug development with our unique
science and technology and also through open collaboration with global partners.
-
Bioinformatics & Artificial Intelligence
Sovargen is awaiting its partners to collaborate on articulating root causes and mechanisms of CNS diseases and create a transformational long-term platform.- Programs for Cooperation
-
- Genomic data base target discovery
- In vitro and in vivo Target validation
- RNA drugs candidate screening & optimization
-
RNA
Sovargen is awaiting its partners to design and materialize a new gene treatment technology
Therapeutics- Programs for Cooperation
-
- ASO, siRNA therapy
- mRNA therapy
- chemical modification of ASO, siRNA, mRNA
- Gene editing
-
Delivery System Development
Sovargen is awaiting its partners to develop new drug delivery systems by which the in vivo stability and the permeability of the blood-brain barrier or BBB, will be further enhanced.- Programs for Cooperation
-
- Liposome
- Exosome
- Viral Vector
-
New Disease Models
Sovargen is awaiting its partners to build disease-specific animal models with the new gene -editing technology to validate the stability and effectiveness of candidate substances.- Programs for Cooperation
-
- Human brain organoid, iPSC
- Genetic engineered animal model